These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 38955698)

  • 1. [Application of 21-gene recurrence risk score in patients with breast cancer].
    Chen Q; Shen HX; Wang YL; Zhao J; Ma JF; Wang SQ; Fu PF
    Zhonghua Bing Li Xue Za Zhi; 2024 Jul; 53(7):678-684. PubMed ID: 38955698
    [No Abstract]   [Full Text] [Related]  

  • 2. Practice Changing Potential of TAILORx: A Retrospective Review of the National Cancer Data Base from 2010 to 2015.
    Reyes SA; De La Cruz LM; Ru M; Pisapati KV; Port E
    Ann Surg Oncol; 2019 Oct; 26(10):3397-3408. PubMed ID: 31429016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distribution patterns of 21-gene recurrence score in 980 Chinese estrogen receptor-positive, HER2-negative early breast cancer patients.
    Wu J; Fang Y; Lin L; Fei X; Gao W; Zhu S; Zong Y; Chen X; Huang O; He J; Zhu L; Chen W; Li Y; Shen K
    Oncotarget; 2017 Jun; 8(24):38706-38716. PubMed ID: 28404972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Prognostic Significance of the Oncotype DX Recurrence Score in T
    Wang M; Wu K; Zhang P; Zhang M; Ding A; Chen H
    Ann Surg Oncol; 2019 May; 26(5):1227-1235. PubMed ID: 30456680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is Routine Recurrence Score Testing in Patients Older than 70 Years of Age Warranted? An Evaluation of the National Cancer Database After TAILORx.
    Lee RM; Switchenko JM; Ho TB; Arciero CA; Bhave MA; Subhedar PD
    Ann Surg Oncol; 2019 Oct; 26(10):3152-3158. PubMed ID: 31342377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Impact of the 21-gene recurrence score assay in clinical treatment and prognosis analysis for patients with hormone receptor positive early-stage breast cancer].
    Zhang YN; Zhou YD; Mao F; Guan JH; Lin Y; Wang XJ; Shen SJ; Wang CJ; Yao R; Sun Q
    Zhonghua Zhong Liu Za Zhi; 2018 Feb; 40(2):110-114. PubMed ID: 29502370
    [No Abstract]   [Full Text] [Related]  

  • 7. Adjuvant chemotherapy and survival among patients 70 years of age and younger with node-negative breast cancer and the 21-gene recurrence score of 26-30.
    Park S; Han Y; Liu Y; Toriola AT; Peterson LL; Colditz GA; Kim SI; Cho YU; Park BW; Park Y
    Breast Cancer Res; 2019 Oct; 21(1):110. PubMed ID: 31619259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Estrogen receptors, Progesterone receptors and HER2-neu immunohistochemistry results in breast cancer with those of Oncotype Dx.
    Sughayer MA; Alhassoon S; Sughayer HM
    Ann Diagn Pathol; 2020 Aug; 47():151556. PubMed ID: 32592992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the Distribution Pattern of 21-Gene Recurrence Score between Mucinous Breast Cancer and Infiltrating Ductal Carcinoma in Chinese Population: A Retrospective Single-Center Study.
    Wu J; Ding S; Lin L; Fei X; Lin C; Andriani L; Goh C; Huang J; Hong J; Gao W; Zhu S; Wang H; Huang O; Chen X; He J; Li Y; Shen K; Chen W; Zhu L
    Cancer Res Treat; 2020 Jul; 52(3):671-679. PubMed ID: 32019280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are we Overtreating Hormone Receptor Positive Breast Cancer with Neoadjuvant Chemotherapy? Role of OncotypeDx
    Kantor O; Barrera E; Kopkash K; Pesce C; Barrera E; Winchester DJ; Yao K
    Ann Surg Oncol; 2019 Oct; 26(10):3232-3239. PubMed ID: 31342379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Secondary Invasive Breast Events among Patients with Hormone-Positive Breast Cancer and High-Risk Oncotype DX Recurrence Scores 26-30 and ≥31.
    Berger NF; Zimmerman BS; Tharakan S; Suchman K; Cascetta KP; Blanter J; Moshier E; Ru M; Jaffer S; Tiersten A
    Oncology; 2021; 99(11):699-702. PubMed ID: 34425579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance of 21-gene recurrence score assay for hormone receptor-positive, lymph node-negative breast cancer in early stage.
    Yu-Qing Y; Lei W; Mei-Ling H; Jing-Jing X; Mei-Chen W; Jiang W; Jun-Sheng H; Rui L; Nan-Lin L
    Exp Mol Pathol; 2019 Jun; 108():150-155. PubMed ID: 31026440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of the 21-Gene Breast Recurrence Score® assay for hormone receptor-positive/human epidermal growth factor 2-negative advanced breast cancer: subanalysis from Japan Breast Cancer Research Group-M07 (FUTURE trial).
    Iwamoto T; Niikura N; Watanabe K; Takeshita T; Kikawa Y; Kobayashi K; Iwakuma N; Okamura T; Kobayashi T; Katagiri Y; Kitada M; Tomioka N; Miyoshi Y; Shigematsu H; Miyashita M; Ishiguro H; Masuda N; Saji S
    Breast Cancer Res Treat; 2024 Nov; 208(2):253-262. PubMed ID: 38922548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of TAILORx on chemotherapy prescribing and 21-gene recurrence score-guided treatment costs in a population-based cohort of patients with breast cancer.
    Tesch ME; Speers C; Diocee RM; Gondara L; Peacock SJ; Nichol A; Lohrisch CA
    Cancer; 2022 Feb; 128(4):665-674. PubMed ID: 34855202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the 12-Gene Molecular Score and the 21-Gene Recurrence Score as Predictors of Response to Neo-adjuvant Chemotherapy in Estrogen Receptor-Positive, HER2-Negative Breast Cancer.
    Soliman H; Wagner S; Flake DD; Robson M; Schwartzberg L; Sharma P; Magliocco A; Kronenwett R; Lancaster JM; Lanchbury JS; Gutin A; Gradishar W
    Ann Surg Oncol; 2020 Mar; 27(3):765-771. PubMed ID: 31907749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The cell cycle profiling-risk score based on CDK1 and 2 predicts early recurrence in node-negative, hormone receptor-positive breast cancer treated with endocrine therapy.
    Kim SJ; Masuda N; Tsukamoto F; Inaji H; Akiyama F; Sonoo H; Kurebayashi J; Yoshidome K; Tsujimoto M; Takei H; Masuda S; Nakamura S; Noguchi S
    Cancer Lett; 2014 Dec; 355(2):217-23. PubMed ID: 25218592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 21-Gene Recurrence Score for prognosis and prediction of taxane benefit after adjuvant chemotherapy plus endocrine therapy: results from NSABP B-28/NRG Oncology.
    Mamounas EP; Tang G; Paik S; Baehner FL; Liu Q; Jeong JH; Kim SR; Butler SM; Jamshidian F; Cherbavaz DB; Sing AP; Shak S; Julian TB; Lembersky BC; Lawrence Wickerham D; Costantino JP; Wolmark N
    Breast Cancer Res Treat; 2018 Feb; 168(1):69-77. PubMed ID: 29128898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of different molecular typing methods and immune status based on RNA sequencing in HR-positive and HER2-negative early-stage breast cancer.
    Ren X; Song Y; Zhang Y; Wu H; Chen L; Pang J; Zhou L; Shen S; Liang Z
    BMC Cancer; 2022 May; 22(1):548. PubMed ID: 35568835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of the 6-gene OncoMasTR test in hormone receptor-positive HER2-negative early-stage breast cancer: Comparative analysis with standard clinicopathological factors.
    Lynch SM; Russell NM; Barron S; Wang CA; Loughman T; Dynoodt P; Fender B; Lopez-Ruiz C; O'Grady A; Sheehan KM; Fay J; Amberger-Murphy V; Saha A; Klinger R; Gonzalez CA; Al-Attar N; Rahman A; O'Leary D; Lanigan FT; Bracken AP; Crown J; Kelly CM; O'Connor DP; Gallagher WM
    Eur J Cancer; 2021 Jul; 152():78-89. PubMed ID: 34090143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selection of neoadjuvant treatment based on the 21-GENE test results in luminal breast cancer.
    Morales Murillo S; Gasol Cudos A; Veas Rodriguez J; Canosa Morales C; Melé Olivé J; Vilardell Villellas F; Sanchez Guzman DR; Iglesias Martínez E; Salud Salvia A
    Breast; 2021 Apr; 56():35-41. PubMed ID: 33601299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.